NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

The GuardianThursday, November 6, 2025 at 12:22:47 PM
NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

NHS won’t get cutting-edge drugs unless it pays more, says AstraZeneca boss

AstraZeneca's CEO, Pascal Soriot, has warned that the NHS may only be able to afford cheaper, generic medicines if the UK does not increase its spending on new drugs. He pointed out that the cost-effectiveness thresholds for new medicines have remained unchanged for two decades, which could hinder access to cutting-edge treatments for patients. This situation is concerning as it highlights the potential limitations in healthcare innovation and patient care in the UK, emphasizing the need for a reevaluation of funding strategies to ensure that the NHS can provide the best possible treatments.
— via World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
Interest rates held at 4% by Bank of England
PositiveFinancial Markets
The Bank of England has decided to keep interest rates steady at 4%, following a closely contested vote. This decision comes as the bank believes that inflation in the UK has reached its peak, which is a positive sign for the economy. By maintaining the current rate, the Bank aims to support economic stability and consumer confidence, making it an important development for both borrowers and savers.
UK construction activity falls at fastest pace in over five years
NegativeFinancial Markets
UK construction activity has experienced its sharpest decline in over five years, signaling potential challenges for the economy. This downturn could impact jobs and investment in the sector, raising concerns about the overall health of the construction industry and its ripple effects on related sectors.
The Bank of England left its key interest rate unchanged, slowing but likely not ending a series of reductions in borrowing costs
NeutralFinancial Markets
The Bank of England has decided to keep its key interest rate unchanged, indicating a pause in its series of borrowing cost reductions. This decision comes as the U.K. grapples with persistently high inflation, even amid a sluggish economy and a cooling jobs market. It's a significant moment as it reflects the central bank's cautious approach to balancing economic growth with inflation control.
Banks poised to escape tax rises in Rachel Reeves’s budget
PositiveFinancial Markets
UK banks are set to benefit as the chancellor has opted not to raise taxes on the sector in the upcoming budget. This decision has led to a rise in bank shares, with NatWest and Lloyds seeing significant gains. By keeping taxes stable, the government aims to ensure that banks remain competitive, which is crucial for fostering economic growth. This move is seen as a positive step for the financial sector and could have broader implications for the UK economy.
Flooded UK coalmines could provide low-carbon cheap heat ‘for generations’
PositiveFinancial Markets
A new report highlights the potential of flooded disused coalmines in the UK as a sustainable energy source, capable of providing low-carbon heat to thousands of homes. By utilizing mine water geothermal heat systems, which harness naturally warmed water, this innovative approach could not only help improve living conditions in poorly insulated housing but also assist the UK in achieving its carbon reduction goals. This development is significant as it offers a practical solution to energy needs while addressing environmental concerns.
AstraZeneca Revenue Climbs on Pipeline Strength
PositiveFinancial Markets
AstraZeneca has reported a strong performance in its latest financial results, with a 14% increase in third-quarter core earnings per share and revenue rising to $15.19 billion. This growth highlights the company's robust pipeline and suggests a positive outlook for future developments, making it an important player in the pharmaceutical industry.
Health Care Roundup: Market Talk
NeutralFinancial Markets
In the latest Health Care Roundup, we delve into market insights regarding major players like AstraZeneca, Smith & Nephew, and Novo Nordisk. This information is crucial for investors and stakeholders as it highlights trends and developments that could impact the health care sector significantly.
Health Care Roundup: Market Talk
NeutralFinancial Markets
In the latest Health Care Roundup, we delve into market insights regarding major players like AstraZeneca, Smith & Nephew, and Novo Nordisk. This information is crucial for investors and stakeholders as it highlights trends and developments that could impact the health care sector's future.